PRIMARY AND METASTATIC MUCINOUS OVARIAN CANCER. DIAGNOSTIC DIFFICULTIES AND NEWDEVELOPMENTS IN TREATMENT

Abstract

In order to improve the results of treatment of patients with malignant ovarian tumors the clinical, morphological and genetic characteristics of mucinous tumors were analyzed. There are 4 cases of mucinous ovarian tumors: the case of mucinous cystadenocarcinoma ovarian associated with dermoid cyst; the case of the giant metastases to ovarian from colorectal mucinous adenocarcinoma; the case of mucinous metastases to ovarian associated with malignant mesotheliomas; the case of the low-grade mucinous neoplasm (mucinous cystadenocarcinoma of the appendix) presented with pseudomyxoma peritonei and mucinous ovarian tumor.

Keywords

mucinous cystadenocarcinoma ovarian / metastases to ovarian from colorectal carcinoma / pseudomyxoma peritonei / malignant peritoneal mesotheliomas

References

[1] Горелова И.А. Муцинозные опухоли яичников различного потенциала злокачественности. Автореф. дис.. канд.мед.наук. М., 2008.

[2] Yamao K, Yanagisawa A, Takahashi K et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: A Multi-Institutional Study of the Japan Pancreas Society. Pancreas. 2011 Jan;40(1):67-71. doi: 10.1097/ MPA.0b013e3181f749d3.

[3] Ongom P.A., Odida M., Lukande R., et.al. Metastatic colorectal carcinoma mimicking primary ovarian carcinoma presenting as ‘Giant’ ovarian tumors in an individual with probable Lynch syndrome. J Med Case Rep. 2013; 7 (158).

[4] Benedix F, Kube R, Meyer F, et al. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57-64.

[5] Fujiwara A, Noura S, Ohue M, Shingai T, et.al. Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol 2010, 102(6):582-87.

[6] Kanemitsu Y, Kato T, Hirai T et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003;46:160-67.

[7] NCCN Guidelines Mucinous tumors of ovaries. Version 3.2014 www.nccn.org/patients

[8] Rouzbahman M., Runjan Chetty R. Mucinous tumours of appendix and ovary: an overview and evaluation of current practice. J Clin Pathol 2014;67:193-97.

[9] Tang L, Yang J, Ng SK, Rodriguez N. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010 Jan; 46(1): 170-9.

[10] Morice P., et al. Borderline ovarian tumors: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence The lancet Oncol. 2012; 13; p e103-e115.

[11] Bosman FT, Carneiro F, Hruban RH, (Eds.) WHO Classification of Tumours of the Digestive System. 4th Edition, International Agency for Research on Cancer, Lyon 2010.

[12] Longacre T.A., Prat J., Bell D.A., et.al. Mucinous tumours. WHO Classification of Tumours of Female Reproductive Organs. 4th Edition, Edited by Robert J. Kurman. Lyon 2014, pp. 25-29.

[13] Verhulst J, Ferdinande L, Demetter P, et. al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012; 65(5): 381-88.

[14] Bridda A, Padoan I, Mencarelli R, et.al.// Peritoneal mesothelioma: a review. Med Gen Med 2007, 9:32.

[15] Feldman AL, Libutti SK, PingPank JF, et.al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003, 21:4560-66.

[16] Enomoto T, Weghorst CM, Inoue M, (1991). K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-85.

[17] Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001; 20: 244-51.

[18] Kondi-Pafiti A, Kairi-Vasilatou E, lavazzo C, et.al. Metastatic neoplasms of the ovaries: a clinico-pathological study of 97 cases. Arch Gynecol Obstet 2011, 284:1283-88.

[19] Trial GOG 241. GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/-beva- cizumab compared with oxaliplatin and capecitabine +/-bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer (mEOC); Japanese Gynecologic Oncology Group 3017. Carboplatin/ paclitaxel versus carboplatin/ irinotecan.

[20] Randomized clinical trials of intraperitoneal chemotherapy for advanced stage epithelial ovarian cancer GOG 104/Alberts, 1996 GOG 114/Markman, 2001 GOG 172/Armstrong, 2006 GOG 252.

RIGHTS & PERMISSIONS

Kedrova A.G., Shablovsky О.R., Zabozlaev F.G., Nechaeva О.E., Krasilnikov S.E., Maksimenko T.A., Gerasimov A.A.